{"id":"epoetin-alfa-vials","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"5-10","effect":"Thrombotic events (deep vein thrombosis, pulmonary embolism)"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"5-10","effect":"Fever"},{"rate":"<1","effect":"Pure red cell aplasia (rare)"}]},"_chembl":{"chemblId":"CHEMBL1201565","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoetin alfa is a glycoprotein that mimics endogenous erythropoietin, promoting the proliferation and differentiation of erythroid progenitor cells in the bone marrow. This leads to increased reticulocyte production and elevation of hemoglobin and hematocrit levels. It is used to treat anemia associated with chronic kidney disease, cancer chemotherapy, and other conditions.","oneSentence":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:17.927Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in cancer patients receiving chemotherapy"},{"name":"Anemia in patients undergoing elective surgery"}]},"trialDetails":[{"nctId":"NCT00239616","phase":"PHASE2","title":"Pharmacokinetic of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2002-06-05","conditions":"Anemia","enrollment":10},{"nctId":"NCT01196715","phase":"PHASE3","title":"Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Barts & The London NHS Trust","startDate":"2010-11-01","conditions":"Myelodysplastic Syndrome","enrollment":360},{"nctId":"NCT03457701","phase":"PHASE2","title":"Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-07-30","conditions":"Anaemia","enrollment":15},{"nctId":"NCT03308448","phase":"PHASE3","title":"Traumatic Optic Neuropathy Treatment Trial 2","status":"COMPLETED","sponsor":"Iran University of Medical Sciences","startDate":"2018-01-06","conditions":"Traumatic Optic Neuropathy","enrollment":93},{"nctId":"NCT02811263","phase":"PHASE3","title":"High-dose Erythropoietin for Asphyxia and Encephalopathy","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2017-01","conditions":"Neonatal Encephalopathy, Birth Asphyxia","enrollment":500},{"nctId":"NCT03400033","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-09-05","conditions":"Anaemia","enrollment":407},{"nctId":"NCT03528564","phase":"PHASE2","title":"Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia","status":"TERMINATED","sponsor":"Unity Health Toronto","startDate":"2019-07-01","conditions":"Anemia, Iron Deficiency, Anemia of Chronic Disease, Hip Arthropathy","enrollment":4},{"nctId":"NCT03398473","phase":"PHASE1","title":"A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-01-25","conditions":"Healthy","enrollment":68},{"nctId":"NCT00090753","phase":"PHASE3","title":"A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-10","conditions":"Anemia","enrollment":1228},{"nctId":"NCT00557817","phase":"PHASE2, PHASE3","title":"Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)","status":"COMPLETED","sponsor":"University of Liege","startDate":"2004-03","conditions":"Hematological Malignancies","enrollment":125},{"nctId":"NCT00140010","phase":"PHASE2","title":"Erythropoietin Therapy for Subarachnoid Hemorrhage","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2005-04","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Epoetin alfa vials","genericName":"Epoetin alfa vials","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in cancer patients receiving chemotherapy, Anemia in patients undergoing elective surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}